We compared the internalization of [90Y-DOTA0, Tyr3]octreotide and [111In-DOTA0, Tyr3]octreotide with that of [125I-Tyr3]octreotide and [111In-DTPA0]octreotide in the subtype 2 somatostatin receptor (sst2)-positive rat pancreatic tumour cell lines Ca20948 and AR42) and in the somatostatin receptor-negative human anaplastic thyroid tumour cell line ARO. We demonstrated that [111In-DTPA0]octreotide, [90Y-DOTA0, Tyr3]octreotide and [111In-DOTA0, Tyr3]octreotide are internalized by a receptor-specific, time- and temperature-dependent process. The amount of [90Y-DOTA0, Tyr3]octreotide internalized was higher than that of [111In-DOTA0, Tyr3]octreotide and [111In-DTPA0]octreotide.

dx.doi.org/10.1080/00006231-199803000-00013, hdl.handle.net/1765/105562
Nuclear Medicine Communications
wrong DOI

de Jong, M, Bernard, B.F, Bruin, E.C. (Eric), van Gameren, A, Bakker, W.H, Krenning, E.P, … Mäcke, H.R. (1998). Internalization of radiolabelled [dtpa0]octreotide and [dota0, tyr3]octreotide peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nuclear Medicine Communications, 19(3), 283–288. doi:10.1080/00006231-199803000-00013